November 28, 2021

Medical Trend

Medical News and Medical Resources


Warning: sprintf(): Too few arguments in /www/wwwroot/medicaltrend.org/wp-content/themes/newsphere/lib/breadcrumb-trail/inc/breadcrumbs.php on line 254

New medicine for children ≥10 years old with multidrug-resistant tuberculosis!

New medicine for children ≥10 years old with multidrug-resistant tuberculosis!

New medicine for children ≥10 years old with multidrug-resistant tuberculosis!



 

New medicine for children ≥10 years old with multidrug-resistant tuberculosis!

Otsuka Pharmaceutical‘s Deltyba (Dilamani) 25mg dispersible tablets approved in the EU: treat children ≥10 years old with multidrug-resistant tuberculosis!

Deltyba is a bactericide with a new mechanism of anti-tuberculosis activity that can infect the metabolism of the cell wall of Mycobacterium tuberculosis (MTB).

 

New medicine for children ≥10 years old with multidrug-resistant tuberculosis!

Tuberculosis (picture source: medindia.net)

 

November 10, 2021/ reports/ – Otsuka Pharma recently announced that the European Commission (EC) has approved Deltyba (delamanid) 25mg dispersible tablet formulations . When an effective treatment plan cannot be developed, this Deltyba preparation can be used as part of a drug treatment plan for the treatment of children with pulmonary multidrug-resistant tuberculosis (MDR-TB) weighing ≥10kg .

 

The “Global Tuberculosis Report 2020” compiled by the World Health Organization pointed out that 1.2 million children (0 to 14 years old) suffered from tuberculosis (TB) in 2019. In addition, according to a paper published in the International Journal of Tuberculosis and Lung Disease, 25,000 to 32,000 children worldwide get multidrug-resistant tuberculosis (MDR-TB) every year, and approximately 22% of children with MDR-TB may die . One of the new global goals set by the 2018 UN General Assembly High-Level Meeting on Tuberculosis is to treat 115,000 children with drug-resistant TB within 5 years.

 

Masanori Kawasaki, Head of Otsuka Pharmaceutical’s Global Tuberculosis Project, said: “Otsuka Pharmaceutical has been conducting tuberculosis research and development for many years, with the goal of providing treatments to as many patients as possible and ultimately eradicating tuberculosis worldwide. We hope for the new approval.   The Deltyba dosage form will help children with MDR-TB treatment. We will continue to achieve the Sustainable Development Goals through the development of anti-tuberculosis drugs.”

 

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mycobacterium tuberculosis), which mainly affects the lungs.

Multidrug-resistant tuberculosis refers to tuberculosis that is resistant to at least isoniazid and rifampicin. These two drugs are the two main anti-tuberculosis drugs used in the standard treatment of tuberculosis.

 

Deltyba is a bactericidal drug produced by Otsuka Pharmaceutical. It has a new mechanism of anti-tuberculosis activity and can interfere with the metabolism of Mycobacterium tuberculosis (MTB) cell walls. Deltyba works by inhibiting the synthesis of mycolic acid, which is the basic component of the cell wall of Mycobacterium tuberculosis (MTB).

Deltyba has high bactericidal activity against various MTB strains in vitro, including strains resistant to first-line anti-tuberculosis drugs (such as isoniazid and rifampicin).

 

Currently, Deltyba has been approved in Europe, Japan, South Korea, China , India, South Africa, Russia and other countries.

The drug was added to the WHO Model List of Essential Medicines in 2015 and has been used to treat patients with multidrug-resistant tuberculosis (MDR-TB) in more than 110 countries.

Last year in Europe, Deltyba 50mg film-coated tablets were approved for use in children and adolescents weighing at least 30kg.

 

 

picture source: pharmazeutische-zeitung.de

(source:internet, reference only)


Disclaimer of medicaltrend.org